Through its joint venture with Samsung Bioepis, Biogen Idec has exercised its right to enter an agreement to commercialize anti-TNF biosimilar product candidates in Europe, which include widely used therapies to treat rheumatoid arthritis and Crohn’s disease. The agreement with Samsung Bioepis is part of Biogen’s corporate objectives to remain focused on its core business, while leveraging its manufacturing expertise for biosimilar therapies.   “This is a unique opportunity for us to leverage ou...